Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with bamlanivimab, bamlanivimab-etesevimab, and casirivimab-imdevimab. There was significantly lower hospitalization with casirivimab-imdevimab compared to bamlanivimab or bamlanivimab-etesevimab. PSM and multivariate analysis is only provided for all treatments combined.
risk of death, 77.5% lower, RR 0.23, p = 0.18, treatment 1 of 1,148 (0.1%), control 33 of 8,534 (0.4%), unadjusted.
risk of ICU admission, 47.5% lower, RR 0.52, p = 0.14, treatment 6 of 1,148 (0.5%), control 85 of 8,534 (1.0%), unadjusted.
risk of hospitalization, 52.4% lower, RR 0.48, p < 0.001, treatment 45 of 1,148 (3.9%), control 703 of 8,534 (8.2%), unadjusted.
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
Cooper et al., 10/8/2021, retrospective, USA, North America, peer-reviewed, 9 authors.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical significance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.